Reata Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RETA research report →
Companywww.reatapharma.com
Reata Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.
- CEO
- J. Warren Huff
- IPO
- 2016
- Employees
- 321
- HQ
- Plano, TX, US
Price Chart
Valuation
- Market Cap
- $6.57B
- P/E
- -20.07
- P/S
- 2963.20
- P/B
- -95.29
- EV/EBITDA
- -24.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -12191.11%
- Net Margin
- -14074.95%
- ROE
- 47.21%
- ROIC
- -59.02%
Growth & Income
- Revenue
- $2.22M · -80.71%
- Net Income
- $-311,901,000 · -4.88%
- EPS
- $-8.59 · -4.88%
- Op Income
- $-270,155,000
- FCF YoY
- 12.44%
Performance & Tape
- 52W High
- $172.46
- 52W Low
- $21.83
- 50D MA
- $157.27
- 200D MA
- $94.36
- Beta
- 1.42
- Avg Volume
- 954.09K
Get TickerSpark's AI analysis on RETA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 26, 23 | Desai Antal Rohit | sell | 993,929 |
| Sep 26, 23 | Desai Antal Rohit | sell | 134 |
| Sep 26, 23 | McGaughy R Kent Jr | sell | 2,773 |
| Sep 26, 23 | McGaughy R Kent Jr | sell | 690 |
| Sep 26, 23 | McGaughy R Kent Jr | sell | 3,185 |
| Sep 26, 23 | McGaughy R Kent Jr | sell | 6,000 |
| Sep 26, 23 | McGaughy R Kent Jr | sell | 280 |
| Sep 26, 23 | McGaughy R Kent Jr | sell | 278,309 |
| Sep 26, 23 | McGaughy R Kent Jr | sell | 699 |
| Sep 26, 23 | McGaughy R Kent Jr | sell | 4,787 |
Our RETA Coverage
We haven't published any research on RETA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RETA Report →